{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:53:21Z","timestamp":1794434001614,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Karuna Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schizophr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    KarXT combines xanomeline, an M\n                    <jats:sub>1<\/jats:sub>\n                    \/M\n                    <jats:sub>4<\/jats:sub>\n                    preferring muscarinic agonist with no direct D\n                    <jats:sub>2<\/jats:sub>\n                    receptor antagonism, with the peripherally restricted anticholinergic trospium. In EMERGENT-1 (NCT03697252), a 5-week, randomized, double-blind, placebo-controlled, phase 2 study in inpatients with schizophrenia, KarXT met the primary efficacy endpoint, numerous secondary endpoints, and was generally well tolerated. Here, we conducted additional post hoc analyses of safety and tolerability data of KarXT from EMERGENT-1 with a particular focus on adverse events (AEs) that may be associated with muscarinic receptor agonism (nausea or vomiting) or antagonism (dry mouth or constipation). A total of 179 patients received at least one dose of either KarXT (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200989) or placebo (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200990) and were included in the analyses. KarXT was associated with a low overall AE burden. The majority of procholinergic and anticholinergic AEs with KarXT were mild, occurred in the first 1\u22122 weeks of treatment, and were transient with a median duration ranging from 1 day for vomiting to 13 days for dry mouth. No patients in either treatment group discontinued the study due to any procholinergic or anticholinergic AEs. Incidence of somnolence\/sedation AEs with KarXT were low and similar to those in the placebo group. KarXT was associated with no significant or clinically relevant changes in body weight, metabolic parameters, or vital signs. KarXT was generally well tolerated with an AE profile consistent with the activity of xanomeline\u2013trospium at muscarinic receptors.\n                  <\/jats:p>","DOI":"10.1038\/s41537-022-00320-1","type":"journal-article","created":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T05:02:50Z","timestamp":1670043770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Safety and tolerability of KarXT (xanomeline\u2013trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia"],"prefix":"10.1038","volume":"8","author":[{"given":"Christoph U.","family":"Correll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel S.","family":"Angelov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5583-5871","authenticated-orcid":false,"given":"Peter J.","family":"Weiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen K.","family":"Brannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,3]]},"reference":[{"key":"320_CR1","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/s41380-019-0502-5","volume":"26","author":"RA McCutcheon","year":"2021","unstructured":"McCutcheon, R. A. et al. The efficacy and heterogeneity of antipsychotic response in schizophrenia: A meta-analysis. Mol. Psychiatry 26, 1310\u20131320 (2021).","journal-title":"Mol. Psychiatry"},{"key":"320_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/TCRM.S117321","volume":"13","author":"M Solmi","year":"2017","unstructured":"Solmi, M. et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther. Clin. Risk. Manag. 13, 757\u2013777 (2017).","journal-title":"Ther. Clin. Risk. Manag."},{"key":"320_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.4088\/PCC.v07n0602","volume":"7","author":"A Farah","year":"2005","unstructured":"Farah, A. Atypicality of atypical antipsychotics. Prim. Care Companion J. Clin. Psychiatry 7, 268\u2013274 (2005).","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"320_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/00131746-200701000-00003","volume":"13","author":"PJ Weiden","year":"2007","unstructured":"Weiden, P. J. EPS profiles: the atypical antipsychotics are not all the same. J. Psychiatr. Pract. 13, 13\u201324 (2007).","journal-title":"J. Psychiatr. Pract."},{"key":"320_CR5","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn, M. et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394, 939\u2013951 (2019).","journal-title":"Lancet"},{"key":"320_CR6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/wps.20579","volume":"17","author":"M Carbon","year":"2018","unstructured":"Carbon, M., Kane, J. M., Leucht, S. & Correll, C. U. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry 17, 330\u2013340 (2018).","journal-title":"World Psychiatry"},{"key":"320_CR7","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.4088\/JCP.16r10832","volume":"78","author":"M Carbon","year":"2017","unstructured":"Carbon, M., Hsieh, C. H., Kane, J. M. & Correll, C. U. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. J. Clin. Psychiatry 78, e264\u2013e278 (2017).","journal-title":"J. Clin. Psychiatry"},{"key":"320_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.schres.2021.08.013","volume":"237","author":"Y Zhu","year":"2021","unstructured":"Zhu, Y. et al. Prolactin levels influenced by antipsychotic drugs in schizophrenia: A systematic review and network meta-analysis. Schizophr. Res. 237, 20\u201325 (2021).","journal-title":"Schizophr. Res."},{"key":"320_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-020-00292-5","volume":"19","author":"R Tandon","year":"2020","unstructured":"Tandon, R. et al. The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey. Ann. Gen. Psychiatry 19, 42 (2020).","journal-title":"Ann. Gen. Psychiatry"},{"key":"320_CR10","doi-asserted-by":"crossref","unstructured":"Krogmann, A. et al. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. C.N.S. Spectr. 24, 38\u201369 (2019).","DOI":"10.1017\/S109285291900124X"},{"key":"320_CR11","doi-asserted-by":"publisher","first-page":"SU21204IP21201","DOI":"10.4088\/JCP.SU21204IP1","volume":"83","author":"CU Correll","year":"2022","unstructured":"Correll, C. U., Abi-Dargham, A. & Howes, O. Emerging treatments in schizophrenia. J. Clin. Psychiatry 83, SU21204IP21201 (2022).","journal-title":"J. Clin. Psychiatry"},{"key":"320_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/(SICI)1098-2299(199702)40:2<158::AID-DDR6>3.0.CO;2-K","volume":"40","author":"FP Bymaster","year":"1997","unstructured":"Bymaster, F. P. et al. Xanomeline: a selective muscarinic agonist for the treatment of Alzheimer\u2019s disease. Drug Dev. Res. 40, 158\u2013170 (1997).","journal-title":"Drug Dev. Res."},{"key":"320_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejphar.2008.12.044","volume":"605","author":"JN Heinrich","year":"2009","unstructured":"Heinrich, J. N. et al. Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur. J. Pharmacol. 605, 53\u201356 (2009).","journal-title":"Eur. J. Pharmacol."},{"key":"320_CR14","unstructured":"Powers, A. S. et al. Molecular mechanism of antipsychotic xanomeline\u2019s selectivity at muscarinic receptors. Presented at: American College of Neuropsychopharmacology, San Juan, Puerto Rico (December 6-9, 2020)."},{"key":"320_CR15","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1097\/00002093-199703000-00004","volume":"11","author":"NC Bodick","year":"1997","unstructured":"Bodick, N. C. et al. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 11, S16\u2013S22 (1997).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"320_CR16","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","volume":"165","author":"A Shekhar","year":"2008","unstructured":"Shekhar, A. et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry 165, 1033\u20131039 (2008).","journal-title":"Am. J. Psychiatry"},{"key":"320_CR17","doi-asserted-by":"crossref","unstructured":"Paul, S. M. et al. Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia. Am. J. Psychiatry, appiajp21101083 (2022).","DOI":"10.1176\/appi.ajp.21101083"},{"key":"320_CR18","doi-asserted-by":"crossref","unstructured":"Felder, C. C. et al. Elucidating the role of muscarinic receptors in psychosis. Life Sci. 68, 2605\u20132613 (2001).","DOI":"10.1016\/S0024-3205(01)01059-1"},{"key":"320_CR19","unstructured":"Indevus Pharmaceuticals. Sanctura (trospium chloride). Prescribing Information. (2012)."},{"key":"320_CR20","doi-asserted-by":"crossref","unstructured":"Staskin, D. et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int. J. Clin. Pract. 64, 1294\u20131300 (2010).","DOI":"10.1111\/j.1742-1241.2010.02433.x"},{"key":"320_CR21","unstructured":"Kavoussi, R., Miller, A., Brannan, S. & Breier, A. Results of a double-blind, placebo-controlled, tolerability study of KarXT, a novel combination targeting muscarinic acetylcholine receptors using xanomeline with trospium chloride to mitigate cholinergic side effects. Presented at: American Society of Clinical Psychopharmacology Annual Meeting, Miami Beach, FL (May 29-June 2, 2017)."},{"key":"320_CR22","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa2017015","volume":"384","author":"SK Brannan","year":"2021","unstructured":"Brannan, S. K. et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N. Engl. J. Med. 384, 717\u2013726 (2021).","journal-title":"N. Engl. J. Med."},{"key":"320_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physiolgenomics.00062.2017","volume":"50","author":"HC Saternos","year":"2018","unstructured":"Saternos, H. C. et al. Distribution and function of the muscarinic receptor subtypes in the cardiovascular system. Physiol. Genomics 50, 1\u20139 (2018).","journal-title":"Physiol. Genomics"},{"key":"320_CR24","doi-asserted-by":"crossref","unstructured":"De Hert, M. et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat. Rev. Endocrinol. 8, 114\u2013126 (2011).","DOI":"10.1038\/nrendo.2011.156"},{"key":"320_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","volume":"7","author":"T Pillinger","year":"2020","unstructured":"Pillinger, T. et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 7, 64\u201377 (2020).","journal-title":"Lancet Psychiatry"},{"key":"320_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1176\/appi.ajp.161.1.116","volume":"161","author":"MJ Minzenberg","year":"2004","unstructured":"Minzenberg, M. J., Poole, J. H., Benton, C. & Vinogradov, S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am. J. Psychiatry 161, 116\u2013124 (2004).","journal-title":"Am. J. Psychiatry"},{"key":"320_CR27","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1176\/appi.ajp.2009.09010017","volume":"166","author":"S Vinogradov","year":"2009","unstructured":"Vinogradov, S. et al. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am. J. Psychiatry 166, 1055\u20131062 (2009).","journal-title":"Am. J. Psychiatry"},{"key":"320_CR28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4088\/PCC.v06n0101","volume":"6","author":"DD Miller","year":"2004","unstructured":"Miller, D. D. Atypical antipsychotics: sleep, sedation, and efficacy. Prim. Care Companion J. Clin. Psychiatry 6, 3\u20137 (2004).","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"320_CR29","unstructured":"Krystal, J., et al. CVL-231 as a novel positive allosteric modulator targeting M4 muscarinic receptors: results from a phase 1b trial in patients with schizophrenia. Presented at: Hybrid Congress of the Schizophrenia International Research Society, Florence, Italy."},{"key":"320_CR30","unstructured":"Data on file, Karuna Therapeutics."},{"key":"320_CR31","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.jpsychires.2013.07.011","volume":"47","author":"Z Fan","year":"2013","unstructured":"Fan, Z. et al. Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. J. Psychiatr. Res. 47, 1549\u20131556 (2013).","journal-title":"J. Psychiatr. Res."},{"key":"320_CR32","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1017\/S0033291712000396","volume":"42","author":"M Lahti","year":"2012","unstructured":"Lahti, M. et al. Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia. Psychol. Med. 42, 2275\u20132285 (2012).","journal-title":"Psychol. Med."},{"key":"320_CR33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.schres.2011.06.008","volume":"131","author":"TM Laursen","year":"2011","unstructured":"Laursen, T. M. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr. Res. 131, 101\u2013104 (2011).","journal-title":"Schizophr. Res."},{"key":"320_CR34","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3389\/fpsyt.2014.00137","volume":"5","author":"PA Ringen","year":"2014","unstructured":"Ringen, P. A. et al. Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions. Front. Psychiatry 5, 137 (2014).","journal-title":"Front. Psychiatry"},{"key":"320_CR35","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1017\/S2045796017000166","volume":"27","author":"J Westman","year":"2018","unstructured":"Westman, J. et al. Increased cardiovascular mortality in people with schizophrenia: a 24-year national register study. Epidemiol. Psychiatr. Sci. 27, 519\u2013527 (2018).","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"320_CR36","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/wps.20994","volume":"21","author":"CU Correll","year":"2022","unstructured":"Correll, C. U. et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry 21, 248\u2013271 (2022).","journal-title":"World Psychiatry"},{"key":"320_CR37","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/wps.20420","volume":"16","author":"CU Correll","year":"2017","unstructured":"Correll, C. U. et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 16, 163\u2013180 (2017).","journal-title":"World Psychiatry"},{"key":"320_CR38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.schres.2005.12.855","volume":"83","author":"MA De Hert","year":"2006","unstructured":"De Hert, M. A. et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr. Res. 83, 87\u201393 (2006).","journal-title":"Schizophr. Res."},{"key":"320_CR39","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/wps.20252","volume":"14","author":"D Vancampfort","year":"2015","unstructured":"Vancampfort, D. et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 14, 339\u2013347 (2015).","journal-title":"World Psychiatry"},{"key":"320_CR40","doi-asserted-by":"crossref","unstructured":"Barton, B. B. et al. Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. Expert Opin. Drug Saf. 19, 295\u2013314 (2020).","DOI":"10.1080\/14740338.2020.1713091"},{"key":"320_CR41","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association D. S. M. Task Force. Diagnostic and Statistical Manual of Mental Disorders: DSM-5 (American Psychiatric Association, Arlington, VA, 2013).","DOI":"10.1176\/appi.books.9780890425596"},{"key":"320_CR42","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay, S. R., Fiszbein, A. & Opler, L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261\u2013276 (1987).","journal-title":"Schizophr. Bull."},{"key":"320_CR43","unstructured":"Guy, W. ECDEU Assessment Manual for Psychopharmacology (U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD, 1976)."}],"container-title":["Schizophrenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41537-022-00320-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-022-00320-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-022-00320-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T05:13:42Z","timestamp":1670217222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41537-022-00320-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,3]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["320"],"URL":"https:\/\/doi.org\/10.1038\/s41537-022-00320-1","relation":{},"ISSN":["2754-6993"],"issn-type":[{"value":"2754-6993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,3]]},"assertion":[{"value":"8 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The sponsor was involved in the design and conduct of the study; collection, analysis, and interpretation of data; preparation, review, and approval of the manuscript; and the decision to submit the manuscript for publication. Dr. Correll has been a consultant and\/or advisor to or has received honoraria from AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen\/Johnson & Johnson, Karuna Therapeutics, LB Pharma, Lundbeck, MedAvante-ProPhase, MedinCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris; provided expert testimony for Janssen and Otsuka; served on a Data Safety Monitoring Board for Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva; has received grant support from Janssen and Takeda; received royalties from UpToDate; and is a stock option holder of Cardio Diagnostics, Mindpax, and LB Pharma. Drs. Angelov, Miller, Weiden, and Brannan are employees of and hold equity in Karuna Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"109"}}